The JPMorgan Healthcare Conference typically frontloads the conference putting most, if not all, of the heavy hitters' presentations in the first couple of days of the four-day event.
So, it's no surprise that a company the size of Dendreon was pulling up the rear or, if you want to think it was placed towards the end to keep people around, batting cleanup at the conference when it presented today.
Because I did a live interview on Tuesday from JPM with DNDN CEO Dr. Mitchell Gold I didn't even bother to listen to the webcast of his presentation this afternoon. That'll teach me. I mean, only two days ago he affirmed that the results of the oh-so-crucial test of the company's prostate cancer treatment were still expected around mid-year.